Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Paralegal

Sarah Mackin

Goodwin Procter

main

Mackin Sarah

Sarah Mackin from Washington DC, practices in Private Equity, among many other areas. 

Sarah Mackin

Areas of Practice

Credentials

Related Content

Goodwin Advises Scholar Rock with Its $550 Million Six-Year Credit Facility from Blue Owl Capital

Goodwin Advises Tenpoint Therapeutics on Securing $235 Million Through Series B Stock Financing and Credit Facility

Goodwin Advises Moderna with Its $1.5 Billion Five-Year Credit Facility from Ares Management

Novo Holdings Completes $16.5 Billion Acquisition of Catalent

Goodwin Represents Loparex in Uptier Exchange Liability Management Transaction

iRobot Enters Financing Facility and Modifies Amazon Merger Price

SunMed Acquires Vyaire Medical’s Respiratory and Anesthesia Consumables Business

Moderna and Generation Bio Announce $76 Million Strategic Collaboration to Develop Non-Viral Genetic Medicines

Private Equity